<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Vecuronium</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01339</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01339/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01339/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01339.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01339.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01339.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01339.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01339.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01339">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>50700-72-6</td></tr><tr><th>Weight</th><td>Average: 557.8274<br>Monoisotopic: 557.431833322</td></tr><tr><th>Chemical Formula</th><td>C<sub>34</sub>H<sub>57</sub>N<sub>2</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>BGSZAXLLHYERSY-XQIGCQGXSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl]-1-methylpiperidin-1-ium</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@H](OC(C)=O)[C@H](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Steroid Esters</td></tr><tr><th>Direct parent</th><td>Steroid Esters</td></tr><tr><th>Alternative parents</th><td>Androgens and Derivatives; Piperidines; Tertiary Amines; Carboxylic Acid Esters; Enolates; Polyamines; Ethers</td></tr><tr><th>Substituents</th><td>piperidine; tertiary amine; carboxylic acid ester; enolate; ether; carboxylic acid derivative; polyamine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the steroid esters. These are compounds containing a steroid moeity which bears a carboxylic acid ester group.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Vecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.</td></tr><tr><th>Pharmacodynamics</th><td>Vecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia.</td></tr><tr><th>Mechanism of action</th><td>Vecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>100%</p></td></tr><tr><th>Route of elimination</th><td>Fecal (40-75%) and renal (30% as unchanged drug and metabolites)</td></tr><tr><th>Half life</th><td>51&#8211;80 minutes</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.8913</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.878</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5457</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.77</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.6962</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.6508</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6862</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8382</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.7638</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.742</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9229</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.9368</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7499
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9265
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8557
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6653 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9021
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7784
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.bedfordlabs.com">Bedford Labs</a></li>
<li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.organonshop.com">Organon Pharmaceuticals</a></li>
<li><a href="http://www.pharmedium.com">Pharmedium</a></li>
<li>Schein Pharmaceutical Inc.</li>
<li><a href="http://www.sunpharma.com">Sun Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.junyepharm.com">Zhejiang Xianju Pharmaceutical Co. Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Powder, for solution</td><td>Intravenous</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00479">Amikacin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01223">Aminophylline</a></td><td>Theophylline decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00993">Azathioprine</a></td><td>The agent decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00443">Betamethasone</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Betamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01190">Clindamycin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01111">Colistimethate</a></td><td>Colistimethate may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis. </td></tr><tr><td><a href="/drugs/DB01285">Corticotropin</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Corticotropin. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB01380">Cortisone acetate</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Cortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Dexamethasone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB00687">Fludrocortisone</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Fludrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Phenytoin decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00798">Gentamicin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00741">Hydrocortisone</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Hydrocortisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB01627">Lincomycin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01033">Mercaptopurine</a></td><td>The agent dereases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00959">Methylprednisolone</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Methylprednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB00955">Netilmicin</a></td><td>The agent increases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB01303">Oxtriphylline</a></td><td>Theophylline decreases the effect of muscle relaxant</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00319">Piperacillin</a></td><td>The agent increases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00781">Polymyxin B Sulfate</a></td><td>Polymyxin B may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Consider alternate therapy or monitor for prolonged neuromuscular blocking effects, such as respiratory paralysis. </td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Prednisone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>The quinine derivative increases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>Quinine may increase the neuromuscular blocking action of Vecuronium. Risk of respiratory depression and apnea. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00277">Theophylline</a></td><td>Theophylline decreases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>The agent increases the effect of the muscle relaxant</td></tr><tr><td><a href="/drugs/DB00620">Triamcinolone</a></td><td>Vecuronium may increase the adverse neuromuscular effects of systemic corticosteroids, such as Triamcinolone. Monitor for increased muscle weakness and signs of polyneuropathies and myopathy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>